Doxorubicin Hydrochloride Injectable, Liposomal
Product Images NDC 70710-1530

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 70710-1530). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 01)

Chemical structure of doxorubicin hydrochloride, the active ingredient in DOXORUBICIN HYDROCHLORIDE injectable liposomal formulation by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 02)

Chemical structure of a phospholipid component, likely related to the liposomal formulation of the drug doxorubicin hydrochloride. The structure includes a glycerol backbone esterified to fatty acid chains and a phosphate group bound to a sodium ion, with a polymer chain represented by 'n = ca. 45.'*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 03)

Chemical structure diagram illustrating the molecular formula of a liposomal component with variable chain lengths (m, n = 14 or 16), showing phosphate, oxygen, carbon, and nitrogen atoms arranged in a complex lipid structure.*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 04)

An illustration of the liposomal structure of doxorubicin hydrochloride injectable, showing an aqueous core with entrapped doxorubicin HCl, surrounded by a liposomal bilayer, and an outer MPEG-DSPE coating.*

FDA Label Image

Image (6ba8cf1f 0639 4db5 A864 37077551bb70 130 2)

A Kaplan-Meier survival curve chart showing percent of subjects progression-free over time in months. It compares two groups: Doxorubicin + Bortezomib and Bortezomib alone, with corresponding progression-free percentages and censoring marks. The graph includes p-value and hazard ratio statistics, and a table of subjects at risk for each time point.*

FDA Label Image

Doxorubicin HCl Injection-10ml-container (6ba8cf1f 0639 4db5 A864 37077551bb70 05)

DOXOrubicin Hydrochloride Liposome Injection 2 mg/mL, 20 mg/10 mL single-dose vial for intravenous use. The label includes storage instructions to refrigerate at 2° to 8°C and not to freeze. It states the product is sterile, cytotoxic, requires dilution, and is distributed by Zydus Pharmaceuticals (USA) Inc., manufactured by Zydus Lifesciences Ltd., India. The label also warns not to substitute this liposomal formulation for standard doxorubicin hydrochloride.*

FDA Label Image

Doxorubicin HCl Injection-10ml-carton (6ba8cf1f 0639 4db5 A864 37077551bb70 06)

The packaging label for DOXOrubicin Hydrochloride Liposome Injection contains 20 mg/10 mL (2 mg/mL) in a 10 mL single-dose vial. The label notes it is a liposomal formulation, cytotoxic agent, must be diluted, and intended for intravenous infusion only after dilution. It includes storage instructions to refrigerate at 2° to 8°C and not to freeze. The labeler is Zydus Pharmaceuticals USA Inc., and manufacturing information references Zydus Lifesciences Ltd., Ahmedabad, India.*

FDA Label Image

Doxorubicin HCl Injection-25ml-container (6ba8cf1f 0639 4db5 A864 37077551bb70 07)

Label for DOXOrubicin Hydrochloride Liposome Injection, 50 mg/25 mL (2 mg/mL) single-dose vial. The injectable, liposomal formulation is for intravenous use and distributed by Zydus Pharmaceuticals USA Inc. It is manufactured by Zydus Lifesciences Ltd in Ahmedabad, India. The label includes storage instructions, barcode, and a warning indicating this liposomal formulation should not be substituted for doxorubicin hydrochloride.*

FDA Label Image

Doxorubicin HCl Injection-25ml-carton (6ba8cf1f 0639 4db5 A864 37077551bb70 08)

Packaging label for DOXOrubicin Hydrochloride Liposome Injection 50 mg/25 mL (2 mg/mL) injectable liposomal solution. The label includes dosage strength, dilution instructions, storage conditions, and manufacturer information from Zydus Pharmaceuticals USA Inc. It specifies intravenous use only, single-dose vial, and states the formulation is liposomal and cytotoxic with a clear warning not to substitute for doxorubicin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.